Seed Investments, the early-stage investment and company creation team of Copenhagen, Denmark-based Novo Holdings, today published its review of 2023.
The Seed Investments team incubates, builds and invests in breakthrough life science companies proactively collaborating with innovators globally and taking the lead in building and investing in early-stage startups. 2023 saw the team focus on ensuring the portfolio has the right conditions to progress towards value inflection points, while continuing to build next generation companies.
Søren Møller, Managing Partner at Seed Investments, said: “2023 has been a successful year for Seed Investments with more than $460m raised to our portfolio. Despite market headwinds faced by biotech companies, we continued to actively invest in the sector and continue to see an unparalleled level of innovation. This year, Seed Investments launched SeedLab, our wet laboratory in Denmark, to incubate scientific concepts and novel ideas and thereby reducing risk prior to company creation. As we look forward to 2024, our focus remains on creating and supporting innovative, world class life sciences companies and building experienced teams to accelerate transformative therapies for patients.“
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.